Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

and pharmacokinetics of tezampanel

given once-daily for four consecutive days. Data from this multiple

dose trial are intended to support the continued development of

tezampanel for the treatment of migraine, as well as allow TorreyPines

to consider expanding the development of tezampanel into additional

chronic pain conditions.

-- Completed a Phase I multiple-dose clinical trial of NGX267 in

development for cognitive impairment associated with schizophrenia

(CIAS). NGX267 was found to be safe and well-tolerated. The clinical

trial also demonstrated that NGX267 increases salivary flow, which may

be beneficial in treating xerostomia, or dry mouth.

-- Extended the genetics discovery collaboration with Eisai Co., Ltd.

This agreement focuses on the discovery of Alzheimer's disease targets

using whole-genome family-based association screening. Under terms of

the agreement, TorreyPines received an upfront payment and continued

research funding in support of the program for an additional year.

Financial Results

Revenue for the three month period ended September 30, 2007 was $2.5 million compared to revenue of $2.5 million for the same period in 2006. Operating expenses for the quarter ended September 30, 2007 were $9.5 million, with $8.2 million attributable to research and development. This compares to operating expenses of $5.2 million and research and development expenses of $4.5 million for the same period last year. The Company reported a net loss for the quarter ended September 30, 2007 of $6.8 million compared to a net loss of $2.7 million for the same period last year.

Revenue for the nine month period ended September 30, 2007 was $7.4 million compared to revenue of $7.4 million for the same period in 2006. Operating expenses for the nine month period were $24.6 million, with $20.4 million attributabl
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 Gene synthesis and ... has entered into a technology access and services ... apply DNA2.0’s proprietary protein engineering technology, known as ... “We are extremely excited that the global leader ... This proprietary bioengineering technology has now been validated ...
(Date:12/17/2014)... -- Vermillion, Inc. (NASDAQ: VRML ), a bio-analytic ... next step in its expanded strategy to rebuild the ... naming of current Chief Operating Officer, Valerie Palmieri ... Chairman of the Board and CEO James LaFrance ... are effective January 1, 2015. "Jim and ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
(Date:12/17/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... for rare disorders, announced today its presentation at the ... San Francisco, CA. ... will present on Monday, January 12, 2015, at 9:00 ... webcast live and may be accessed from the "Webcasts ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... The Center for Molecular Biology,(CMB) has received an ... Gates,Foundation to support continued development of an avian ... develop vaccines against,highly pathogenic avian influenza viruses of ... clinical trials. , Dr. ...
... ArunA Biomedical, Inc., announced today that it will make ... in early 2009. The cells, derived from NIH ... normal, consistent population of neural cells in an adherent ... research community. hN2 cells provide a human cell ...
... EUCODIS Bioscience, a company,developing enzymes for the chemical industry, ... Chief Financial Officer. , "We ... brings to,EUCODIS Bioscience," said Rudy Pandjaitan, Ph.D., CEO of ... and his close relations,with the investment community will be ...
Cached Biology Technology:Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development 2ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells 2EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer 2
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 /PRNewswire-USNewswire/ ... efforts to make it easier to detect and ... chain. Today the agency started performing ... The capability will validate the authenticity of purchased ... chain. The new quality control measures will be ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here ... account but can,t remember your password, site key or the ... was your first grade teacher? Today, ... the app that will finally put an end to ... 1U TM . 1U leverages a user,s smartphone ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... While hunting among chimpanzees is a group effort, key ... group. They are more likely to initiate a hunt, and ... study. The findings, which appear in the current issue ... animals cooperate to hunt for food, and how individual variation ...
... Ind. - Purdue University and USDA-Agricultural Research Service scientists ... plants halts infection by a disease-causing fungus that can ... research team is the first to show that the ... grasses - from the devastating, fungal pathogen. The naturally ...
... from an innovative computational approach could speed up the ... development, researchers from the University of Chicago Medical Center ... published in the February 2008 issue of Genome Research, ... of the human genes and proteins that serve as ...
Cached Biology News:Key 'impact hunters' catalyze hunting among male chimpanzees 2Key 'impact hunters' catalyze hunting among male chimpanzees 3Gene guards grain-producing grasses so people and animals can eat 2Gene guards grain-producing grasses so people and animals can eat 3Study of successful drug targets could hasten development of new medications 2Study of successful drug targets could hasten development of new medications 3
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
... The Lambda 10-2 is a microprocessor ... impressive speed coupled with exceptionally smooth ... for research applications involving fluorescence microscopy, ... any application requiring rapid and accurate ...
... FL is equipped with ... measurement technologies that complement ... advanced features of Fluoroskan ... Fluoroskan Ascent FL provides ...
... an enzyme that catalyzes the hydrolysis ... maltotriose, and dextrins. The,level of a-amylase ... body is of,clinical significance in the ... diabetes; plant and microbial a-amylases are,important ...
Biology Products: